Table 1.
Summary of results for evaluation of multiplexed inflammation marker assays
| Bio-Rad number of markers (%) | Millipore number of markers (%) | |
|---|---|---|
|
| ||
| Total | 67 (100.0) | 97 (100.0) |
|
| ||
| Markers with > 25% detection | ||
| Serum | 56 (83.5) | 89 (91.7) |
| Heparin plasma | 63 (94.0) | 89 (91.7) |
| EDTA plasma | 64 (95.5) | 89 (91.7) |
|
| ||
| Markers with < 20% CV for across-batch duplicatesa | ||
| Serum | 51 (76.2) | 75 (77.3) |
| Heparin plasma | 52 (77.6) | 69 (71.1) |
| EDTA plasma | 47 (70.1) | 78 (80.4) |
|
| ||
| ICCs for across-batch duplicates | ||
| Serum | ||
| <0.50 | 6 (8.9) | 5 (5.1) |
| 0.50–0.80 | 29 (43.3) | 32 (33.0) |
| 0.80–0.90 | 12 (17.9) | 19 (19.5) |
| ≥0.90 | 11 (16.4) | 34 (35.1) |
| Heparin plasma | ||
| <0.50 | 3 (4.5) | 9 (9.3) |
| 0.50–0.80 | 38 (56.7) | 31 (31.9) |
| 0.80–0.90 | 15 (22.3) | 25 (25.8) |
| ≥0.90 | 7 (10.4) | 28 (28.9) |
| EDTA plasma | ||
| <0.50 | 5 (7.5) | 7 (7.2) |
| 0.50–0.80 | 49 (73.1) | 25 (25.8) |
| 0.80–0.90 | 5 (7.5) | 24 (24.7) |
| ≥0.90 | 5 (7.5) | 37 (38.1) |
|
| ||
| Markers with acceptable performanceb | 45 (67.2) | 71 (73.2) |
Abbreviations: CV= coefficient of variation; ICC=intraclass correlation coefficient.
a
CVs and ICCs were calculated for 20 blinded duplicate samples for each specimen type that were placed across different batches.
b
Acceptable performance was defined as: 1) being detectable in greater than 25% of the 100 samples on all three specimen types and 2) across-batch CVs of <20% for blinded duplicates placed on at least 2 of the three specimen types.